Alois Rubenbauer reports 65,000 shares in Aspire Biopharma (ASBP) Schedule 13G

Rhea-AI Filing Summary

Aspire Biopharma Holdings, Inc. reports a Schedule 13G filing showing Alois Ryan Rubenbauer III beneficially owns 65,000 shares of Common Stock. The filing states this equals 5.0% of the class based on 1,295,234 shares outstanding as of the quarter ended March 31, 2026. The cover page shows sole voting and dispositive power over 65,000 shares.

Insights

Corporate Governance Analyst

13G reports passive beneficial ownership of 65,000 shares (5.0%).

Alois Ryan Rubenbauer III is listed with 65,000 shares of Common Stock and sole voting and dispositive power over those shares. The filing cites March 31, 2026 as the outstanding-share anchor (1,295,234 shares).

As a Schedule 13G, this indicates a reported passive ownership position rather than an active change in control; future filings could clarify if ownership is maintained or altered.

Key Figures

Beneficially owned shares: 65,000 shares Percent of class: 5.0% Shares outstanding (basis): 1,295,234 shares +1 more

4 metrics

Beneficially owned shares 65,000 shares Reported holding by Alois Ryan Rubenbauer III

Percent of class 5.0% Calculated using outstanding shares as of March 31, 2026

Shares outstanding (basis) 1,295,234 shares Outstanding shares reported in Form 10-Q for quarter ended March 31, 2026

CUSIP 738920305 Security identifier for Common Stock

Key Terms

Schedule 13G, Beneficially owned, Sole Dispositive Power

3 terms

Schedule 13G regulatory

"The filing is titled Schedule 13G and reports beneficial ownership"

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

Beneficially owned financial

"Amount beneficially owned: The information required by Items 4(a)-(c)"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

Sole Dispositive Power financial

"Sole Dispositive Power 65,000.00"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/02/2026 - 08:39 AM Accepted by SEC EDGAR 07/02/2026 - 08:38 AM Learn about SEC filing dates

FAQ

What does Aspire Biopharma (ASBP) Schedule 13G show about ownership?

The filing reports 65,000 shares beneficially owned by Alois Ryan Rubenbauer III, equal to 5.0% of the class. The percentage is calculated using 1,295,234 shares outstanding as of March 31, 2026, per the filing citation.

Does the filer have voting control over the Aspire Biopharma shares?

Yes. The filer reports sole voting power and sole dispositive power over 65,000 shares. The cover page rows show these sole powers tied to the reported holdings.

Is this Schedule 13G an indication of active takeover intent?

No. A Schedule 13G typically reports passive ownership rather than an active acquisition intent. The filing lists beneficial ownership details but does not state any takeover or control plans.

What share count was used to compute the 5.0% ownership figure?

The percentage is based on 1,295,234 shares outstanding as reported in the issuer's Form 10-Q for the quarter ended March 31, 2026. That figure is cited directly in the filing text.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Aspire Biopharma Holdings, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

738920305

(CUSIP Number)

06/25/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 738920305

1

Names of Reporting Persons

Rubenbauer Alois Ryan III

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 65,000.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 65,000.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

65,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.0 %

12

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person: The percentage of the class beneficially owned by the Reporting Person is based on 1,295,234 shares of Common Stock outstanding, as reported by the Issuer in its Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, filed with the Securities and Exchange Commission on May 15, 2026.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Aspire Biopharma Holdings, Inc.
(b)	Address of issuer's principal executive offices: 23150 FASHION DRIVE, SUITE 232, ESTERO, FLORIDA, 33928.
Item 2.
(a)	Name of person filing: Alois Ryan Rubenbauer III (the "Reporting Person").
(b)	Address or principal business office or, if none, residence: 28100 US Highway N., Suite 303, Clearwater, FL 33761.
(c)	Citizenship: The Reporting Person is a citizen of the United States of America.
(d)	Title of class of securities: Common Stock
(e)	CUSIP Number(s): 738920305
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: The information required by Items 4(a)-(c) is set forth in Rows 5-11 of the cover page for the Reporting Person hereto and is incorporated by reference for the Reporting Person.
(b)	Percent of class: The information required by Items 4(a)-(c) is set forth in Rows 5-11 of the cover page for the Reporting Person hereto and is incorporated by reference for the Reporting Person.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: The information required by Items 4(a)-(c) is set forth in Rows 5-11 of the cover page for the Reporting Person hereto and is incorporated by reference for the Reporting Person.
	(ii) Shared power to vote or to direct the vote: The information required by Items 4(a)-(c) is set forth in Rows 5-11 of the cover page for the Reporting Person hereto and is incorporated by reference for the Reporting Person.
	(iii) Sole power to dispose or to direct the disposition of: The information required by Items 4(a)-(c) is set forth in Rows 5-11 of the cover page for the Reporting Person hereto and is incorporated by reference for the Reporting Person.
	(iv) Shared power to dispose or to direct the disposition of: The information required by Items 4(a)-(c) is set forth in Rows 5-11 of the cover page for the Reporting Person hereto and is incorporated by reference for the Reporting Person.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Rubenbauer Alois Ryan III

Signature:	/s/ Alois Ryan Rubenbauer III
Name/Title:	Reporting Person
Date:	07/02/2026